

# Contents

<b>Chapter 1 Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets</b>	<b>1</b>
<i>Guangdi Li and Erik De Clercq</i>	
1.1 Introduction	1
1.2 Viral Targets for Antiviral Drugs	3
1.2.1 Viral Polymerases	3
1.2.2 Viral Integrase	9
1.2.3 Viral Proteases	9
1.2.4 Structural Proteins	10
1.2.5 Accessory Proteins	12
1.3 Host Targets for Antiviral Drugs	13
1.3.1 Host Chemokine Receptors	14
1.3.2 Host Glycoproteins	14
1.3.3 Host Kinases	16
1.3.4 Other Host Proteins	18
1.4 Viral Versus Host Targets	19
1.4.1 Strengths and Weaknesses of Viral Targets	19
1.4.2 Strengths and Weaknesses of Host Targets	19
1.5 Conclusion	20
Conflicts of Interest	20
Acknowledgements	21
References	21

---

Drug Discovery Series No. 80

Antiviral Discovery for Highly Pathogenic Emerging Viruses

Edited by César Muñoz-Fontela and Rafael Delgado

© The Royal Society of Chemistry 2022

Published by the Royal Society of Chemistry, www.rsc.org

<b>Chapter 2</b>	<b>Advances in Prophylaxis and Therapy of Arenavirus Hemorrhagic Fevers</b>	<b>28</b>
	<i>Othmann Merabet and Sylvain Baize</i>	
2.1	Introduction	28
2.2	Therapeutic Approaches Against Arenaviruses	30
	2.2.1 Immunotherapeutic Approaches	30
	2.2.2 Antivirals	33
2.3	Prophylaxis of Arenavirus Infections	35
2.4	Concluding Remarks	38
	References	38
<b>Chapter 3</b>	<b>Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic</b>	<b>45</b>
	<i>César Muñoz-Fontela and Rafael Delgado</i>	
3.1	Origin of the COVID-19 Pandemic Produced by SARS-CoV-2	45
3.2	Coronavirus and Zoonotic Risk	46
3.3	Human Coronaviruses	47
3.4	Structure and Genomic Organization of SARS-CoV-2	48
3.5	Mechanism of Infection and Pathogenesis of SARS-CoV-2	48
3.6	Diagnosis and Kinetics of Respiratory Infection by SARS-CoV-2	49
3.7	The Immune Response to SARS-CoV-2	50
3.8	Vaccine Development for COVID-19	51
3.9	Monoclonal Antibodies Against SARS-CoV-2 for COVID-19 Treatment	51
3.10	Antiviral Development for SARS-CoV-2/COVID-19	53
	References	54
<b>Chapter 4</b>	<b>Small-molecule and Synthetically Derived Antivirals for Ebola Virus and Other Filoviruses</b>	<b>61</b>
	<i>Patrick Iversen, Sandra Bixler, Christopher D. Kane and Travis K. Warren</i>	
4.1	Introduction	61
4.2	Broad-spectrum Nucleobase, Nucleoside, and Nucleotide Antivirals	63
	4.2.1 Remdesivir	63
	4.2.2 Galidesivir	65

<i>Contents</i>	xiii
4.2.3 Favipiravir	66
4.2.4 Other Small Molecules	68
4.3 Emerging Small-molecule and Antiviral Concepts	73
4.3.1 Kinase Inhibitors	73
4.3.2 Compounds with Unknown Mechanisms of Action	74
4.3.3 Alpha-glucosidase Inhibitors	74
4.3.4 Repurposed Drugs	75
4.3.5 $\beta$ -D- $N^4$ -Hydroxycytidine	75
4.3.6 Immunomodulators	75
4.4 Nucleic Acid-based Antivirals	76
4.4.1 Antisense Therapeutics	76
4.5 Small Interfering RNAs	77
4.6 Conclusions	79
Acknowledgements	79
References	80

<b>Chapter 5 Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies</b>	<b>91</b>
<i>Larry Zeitlin, Marc-Antoine de La Vega, Andrew Hiatt and Gary Kobinger</i>	
5.1 Introduction	92
5.2 Introduction to Filoviruses	93
5.2.1 Role of Abs in Natural Infection	93
5.2.2 Role of Abs in Understanding Outbreaks	95
5.2.3 Antibody-dependent Enhancement	96
5.3 The Role of Abs Generated by Experimental Vaccines	97
5.4 Development of Antibodies for Filovirus Medical Countermeasures	101
5.4.1 EBOV mAb Countermeasures	101
5.4.2 Non-EBOV Filoviruses and pan-Ebolavirus mAbs in NHPs	107
5.4.3 Clinical Evaluation of Passive Immunization during the 2013–2016 West Africa Outbreak and the 2018–2020 DRC Outbreak	108
5.4.4 Non-recombinant mAb Alternative Passive Immunization Strategies	109
5.5 Conclusion	110
Acknowledgements	110
References	110

<b>Chapter 6 Vaccine Development in the Midst of <i>Ebolavirus</i> Disease Outbreaks</b>	<b>121</b>
<i>Jayanthi Wolf, Risat Jannat, Sheri Dubey, Sean Troth, Matthew T. Onorato and Jakub K. Simon</i>	
6.1 Introduction	121
6.2 Regulatory Considerations for the Development of an <i>Ebolavirus</i> Vaccine	122
6.2.1 Regulatory Strategy	122
6.2.2 Requirements for Licensure	124
6.2.3 Importance of Interactions with Regulators and Use of Expedited Pathways	127
6.2.4 Access to Vaccine Prior to Licensure	129
6.3 <i>Ebolavirus</i> Vaccine Manufacturing	130
6.3.1 Manufacturing History	130
6.3.2 Considerations for Manufacturing Process Development	132
6.3.3 Considerations for Analytical Test Method Development	133
6.3.4 Production Facility Design	134
6.3.5 Validation of the Manufacturing Process and Analytical Test Methods	136
6.3.6 Vaccine Supply	137
6.4 Non-clinical Immunogenicity and Efficacy Overview	137
6.4.1 Animal Models for <i>Ebolavirus</i> Vaccine Immunogenicity and Efficacy	137
6.4.2 Role of NHP Studies in <i>Ebolavirus</i> Vaccine Licensure	141
6.4.3 Immunoassay Development for NHP Studies	142
6.5 Non-clinical Safety Overview	143
6.5.1 Neurovirulence Assessment	145
6.5.2 Repeat-dose Non-clinical Toxicology Studies	145
6.5.3 Developmental and Reproductive Toxicity	146
6.5.4 Biodistribution	147
6.6 Clinical Development Program	147
6.6.1 The Collaborative Partnership	148
6.6.2 Clinical Trials Assessing Safety, Immunogenicity, and Efficacy	152
6.6.3 Manufacturing Lot Consistency	155
6.6.4 Overall Assessment of Safety	155
6.6.5 Overall Assessment of Immunogenicity	158
6.6.6 Response to Ongoing Outbreaks	159

<i>Contents</i>	xv
6.7 Summary	159
Conflicts of Interest	160
List of Abbreviations	160
Acknowledgements	161
References	161
<b>Chapter 7 Remdesivir: Investigational Antiviral Drug with Activity Against Ebola and Other Emerging and Neglected Viruses</b>	<b>166</b>
<i>Danielle Porter, Becky Norquist and Tomas Cihlar</i>	
7.1 Major Viral Outbreak Threats on the List of WHO High-priority Diseases	166
7.2 Remdesivir and Its Mechanism of Action	168
7.3 Broad-spectrum <i>In Vitro</i> Antiviral Activity of Remdesivir	168
7.4 <i>In Vivo</i> Efficacy of Remdesivir in Animal Models	169
7.4.1 Ebola Virus	170
7.4.2 Marburg Virus	173
7.4.3 MERS Coronavirus	175
7.4.4 SARS Coronavirus	176
7.4.5 Nipah Virus	177
7.4.6 Remdesivir has a High Barrier to Resistance Emergence	178
7.5 Remdesivir Drug Products	178
7.6 Use of Remdesivir in Humans	178
7.7 Summary	180
Abbreviations	180
References	180
<b>Chapter 8 Therapeutics Against Nipah and Hendra Virus</b>	<b>185</b>
<i>Heinz Feldmann and Emmie de Wit</i>	
8.1 Introduction	185
8.1.1 Henipaviruses	185
8.1.2 Hendra and Nipah Virus Outbreaks	186
8.1.3 Clinical Disease	186
8.1.4 Henipavirus Biology	187
8.2 Animal Models of Henipaviral Disease	187
8.2.1 Syrian Hamster Model	188
8.2.2 Ferret Model	188
8.2.3 African Green Monkey Model	188

8.3	Development of Therapeutics – <i>In Vitro</i> Screening of Compounds	188
8.4	Henipavirus Therapeutics	189
8.4.1	Virus-inactivating Compounds	190
8.4.2	Entry/Fusion Inhibitors	192
8.4.3	Inhibition of RNA Replication	197
8.4.4	Host Cell Targets	199
8.5	Discussion	200
	Acknowledgements	201
	References	202
<b>Chapter 9</b>	<b>Glycomimetics as Promising Inhibitors of Ebola Virus, Flavivirus and HIV Infections</b>	<b>208</b>
	<i>Franck Fieschi, Anna Bernardi and Javier Rojo</i>	
9.1	Introduction	208
9.1.1	Glycans and C-type Lectin Receptors: A Major Interface for Sensing Friends or Foes	208
9.1.2	Viral Diversion of C-type Lectin Receptors	210
9.1.3	Designing Drugs Targeting CLRs for Viral Entry Inhibition: Challenges and Bottlenecks	211
9.2	Monovalent Ligands: The Role of Glycomimetics	214
9.3	Carbohydrate Multivalent Ligands as Pathogen Inhibitors	217
9.3.1	Dendron and Dendrimer Scaffolds	218
9.3.2	Carbon Nanoform Scaffolds	221
9.3.3	Metallic Nanoparticle Scaffolds	223
9.3.4	Miscellaneous Scaffolds	224
9.4	Conclusions	225
	Acknowledgements	226
	References	226
<b>Chapter 10</b>	<b>Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses</b>	<b>232</b>
	<i>B. Mercorelli and A. Loregian</i>	
10.1	Introduction to Antiviral Drug Repurposing	232
10.2	Strategies for the Identification of Approved Drugs with Repurposing Potential as Antivirals	233
10.3	Antiviral Drug Repurposing for Highly Pathogenic Emerging Viruses	235
10.3.1	Arenaviruses	235
10.3.2	Ebola Virus and Other Filoviruses	241

<i>Contents</i>	xvii
10.3.3 Zika Virus and West Nile Virus	242
10.3.4 Highly Pathogenic Coronaviruses	244
10.3.5 Nipah and Hendra Virus	246
10.3.6 Influenza Viruses	247
10.4 Future Perspectives	248
Abbreviations	249
Acknowledgements	250
References	250
<b>Chapter 11 Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Viruses</b>	<b>256</b>
<i>Daniel Perez-Zsolt, Javier Martinez-Picado and Nuria Izquierdo-Useros</i>	
11.1 Introduction	256
11.2 Viral Entry into Myeloid Phagocytes	258
11.3 Glycoprotein-dependent Host Attachment Factors	258
11.4 Glycoprotein-independent Host Attachment Factors	260
11.5 Post-attachment Factors Required for Viral Infection	263
11.6 Therapeutic Agents to Block Viral Entry into Myeloid Phagocytes	263
11.7 Concluding Remarks	267
Author Contribution	268
Competing Interest	268
Acknowledgements	268
References	269
<b>Subject Index</b>	<b>280</b>

